Optimizing first-line treatment options for patients with advanced NSCLC

Heather Wakelee, Chandra P. Belani

Research output: Contribution to journalReview article

77 Citations (Scopus)

Abstract

The median survival time for advanced non-small cell lung cancer (NSCLC) remains poor, despite years of research into new chemotherapy combinations. Platinum-based chemotherapy has long been the standard of care for the initial treatment of advanced NSCLC. While no one particular platinum-based chemotherapy regimen is definitely superior to the others (as demonstrated in the Eastern Cooperative Oncology Group's E1594 trial), three randomized phase III trials (the Southwest Oncology Group 9509, Italian Lung Cancer Project, and TAX326 trials) have recently demonstrated that taxane-platinum doublets are better tolerated than a combination of vinorelbine and cisplatin(VC). Moreover, a combination of docetaxel and cisplatin produced superior survival and quality of life than VC in the TAX326 study. Nonplatinum combinations, such as a taxane-gemcitabine doublet, appear promising and better tolerated than their platinum-based comparators in other studies. Efforts to evaluate chemotherapy specifically in elderly patients and in those with poor performance status (PS) have increased. Single-agent chemotherapy has been safely administered to these populations, but platinum-based doublet therapy may also be feasible in both elderly patients and patients with PS scores of 2. The addition of the monoclonal antibody against vascular endothelial growth factor, bevacizumab, to standard chemotherapy for patients with non-squamous cell advanced NSCLC significantly extended median survival in the E4599 randomized trial. Each incremental advance demonstrates that progress can be made in first-line treatment of advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalOncologist
Volume10
Issue numberSUPPL. 3
DOIs
StatePublished - Dec 1 2005

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Drug Therapy
Cisplatin
docetaxel
gemcitabine
Survival
Therapeutics
Standard of Care
Combination Drug Therapy
Vascular Endothelial Growth Factor A
Lung Neoplasms
Monoclonal Antibodies
Quality of Life
Research
Population
taxane
vinorelbine

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{86e59fda23a54f289402aae827c2b594,
title = "Optimizing first-line treatment options for patients with advanced NSCLC",
abstract = "The median survival time for advanced non-small cell lung cancer (NSCLC) remains poor, despite years of research into new chemotherapy combinations. Platinum-based chemotherapy has long been the standard of care for the initial treatment of advanced NSCLC. While no one particular platinum-based chemotherapy regimen is definitely superior to the others (as demonstrated in the Eastern Cooperative Oncology Group's E1594 trial), three randomized phase III trials (the Southwest Oncology Group 9509, Italian Lung Cancer Project, and TAX326 trials) have recently demonstrated that taxane-platinum doublets are better tolerated than a combination of vinorelbine and cisplatin(VC). Moreover, a combination of docetaxel and cisplatin produced superior survival and quality of life than VC in the TAX326 study. Nonplatinum combinations, such as a taxane-gemcitabine doublet, appear promising and better tolerated than their platinum-based comparators in other studies. Efforts to evaluate chemotherapy specifically in elderly patients and in those with poor performance status (PS) have increased. Single-agent chemotherapy has been safely administered to these populations, but platinum-based doublet therapy may also be feasible in both elderly patients and patients with PS scores of 2. The addition of the monoclonal antibody against vascular endothelial growth factor, bevacizumab, to standard chemotherapy for patients with non-squamous cell advanced NSCLC significantly extended median survival in the E4599 randomized trial. Each incremental advance demonstrates that progress can be made in first-line treatment of advanced NSCLC.",
author = "Heather Wakelee and Belani, {Chandra P.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1634/theoncologist.10-90003-1",
language = "English (US)",
volume = "10",
pages = "1--10",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "SUPPL. 3",

}

Optimizing first-line treatment options for patients with advanced NSCLC. / Wakelee, Heather; Belani, Chandra P.

In: Oncologist, Vol. 10, No. SUPPL. 3, 01.12.2005, p. 1-10.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Optimizing first-line treatment options for patients with advanced NSCLC

AU - Wakelee, Heather

AU - Belani, Chandra P.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - The median survival time for advanced non-small cell lung cancer (NSCLC) remains poor, despite years of research into new chemotherapy combinations. Platinum-based chemotherapy has long been the standard of care for the initial treatment of advanced NSCLC. While no one particular platinum-based chemotherapy regimen is definitely superior to the others (as demonstrated in the Eastern Cooperative Oncology Group's E1594 trial), three randomized phase III trials (the Southwest Oncology Group 9509, Italian Lung Cancer Project, and TAX326 trials) have recently demonstrated that taxane-platinum doublets are better tolerated than a combination of vinorelbine and cisplatin(VC). Moreover, a combination of docetaxel and cisplatin produced superior survival and quality of life than VC in the TAX326 study. Nonplatinum combinations, such as a taxane-gemcitabine doublet, appear promising and better tolerated than their platinum-based comparators in other studies. Efforts to evaluate chemotherapy specifically in elderly patients and in those with poor performance status (PS) have increased. Single-agent chemotherapy has been safely administered to these populations, but platinum-based doublet therapy may also be feasible in both elderly patients and patients with PS scores of 2. The addition of the monoclonal antibody against vascular endothelial growth factor, bevacizumab, to standard chemotherapy for patients with non-squamous cell advanced NSCLC significantly extended median survival in the E4599 randomized trial. Each incremental advance demonstrates that progress can be made in first-line treatment of advanced NSCLC.

AB - The median survival time for advanced non-small cell lung cancer (NSCLC) remains poor, despite years of research into new chemotherapy combinations. Platinum-based chemotherapy has long been the standard of care for the initial treatment of advanced NSCLC. While no one particular platinum-based chemotherapy regimen is definitely superior to the others (as demonstrated in the Eastern Cooperative Oncology Group's E1594 trial), three randomized phase III trials (the Southwest Oncology Group 9509, Italian Lung Cancer Project, and TAX326 trials) have recently demonstrated that taxane-platinum doublets are better tolerated than a combination of vinorelbine and cisplatin(VC). Moreover, a combination of docetaxel and cisplatin produced superior survival and quality of life than VC in the TAX326 study. Nonplatinum combinations, such as a taxane-gemcitabine doublet, appear promising and better tolerated than their platinum-based comparators in other studies. Efforts to evaluate chemotherapy specifically in elderly patients and in those with poor performance status (PS) have increased. Single-agent chemotherapy has been safely administered to these populations, but platinum-based doublet therapy may also be feasible in both elderly patients and patients with PS scores of 2. The addition of the monoclonal antibody against vascular endothelial growth factor, bevacizumab, to standard chemotherapy for patients with non-squamous cell advanced NSCLC significantly extended median survival in the E4599 randomized trial. Each incremental advance demonstrates that progress can be made in first-line treatment of advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=31444448873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31444448873&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.10-90003-1

DO - 10.1634/theoncologist.10-90003-1

M3 - Review article

C2 - 16368866

AN - SCOPUS:31444448873

VL - 10

SP - 1

EP - 10

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - SUPPL. 3

ER -